Abstract
| Language | English |
|---|---|
| Pages | 607-613 |
| Number of pages | 7 |
| Journal | Expert Review of Pharmacoeconomics and Outcomes Research |
| Volume | 17 |
| Issue number | 6 |
| Early online date | 13 Apr 2017 |
| DOIs | |
| State | Published - 31 Dec 2017 |
Fingerprint
Keywords
- federal government
- procurement
- Brazil
- medicines
- licensing
Cite this
}
Federal procurement of unlicensed medicines in Brazil : findings and implications. / Teodoro, Cristiane Roberta dos Santos ; dos Reis, André Luís Almeida ; Godman, Brian; Caetano, Rosângela ; Osorio-de-Castro, Claudia Garcia Serpa .
In: Expert Review of Pharmacoeconomics and Outcomes Research, Vol. 17, No. 6, 31.12.2017, p. 607-613.Research output: Contribution to journal › Article
TY - JOUR
T1 - Federal procurement of unlicensed medicines in Brazil
T2 - Expert Review of Pharmacoeconomics and Outcomes Research
AU - Teodoro,Cristiane Roberta dos Santos
AU - dos Reis,André Luís Almeida
AU - Godman,Brian
AU - Caetano,Rosângela
AU - Osorio-de-Castro,Claudia Garcia Serpa
PY - 2017/12/31
Y1 - 2017/12/31
N2 - Background: There are safety concerns with using unlicensed medicines across countries including Brazil. Consequently, this needs to be evaluated and concerns address if pertinent. Aim: Investigate such purchases by the Brazilian Federal Government from 2004 to 2013. Methods: Procurement data from a public-access databank that contains procurement information of the Brazilian Federal Government. Each procured item was cross-referenced to its active drug approval status in the Brazilian National Register (DOU). Exploratory analysis and trend measures were performed for the variables for mapping and characterizing the purchases of non-market approved drugs. Results: 614 (0.14%) purchases in ten years corresponding to 65 unlicensed medicines – some of which had orphan drug status – and 48 different active substances; with a growing trend in recent years. Medicines in 51% of purchases were procured before obtaining marketing approval – with eventual refusals occurring in 17.8% and cancellation due to lack of efficacy and/or safety concerns in 1.1%. Health litigation accounted for 81.9% of purchases and growing in recent years. Conclusions: Overall a low rate of unlicensed medicine use. However, there are concerns given the current regulations in Brazil and the recent increase in the use of unlicensed medicines with increased litigation.
AB - Background: There are safety concerns with using unlicensed medicines across countries including Brazil. Consequently, this needs to be evaluated and concerns address if pertinent. Aim: Investigate such purchases by the Brazilian Federal Government from 2004 to 2013. Methods: Procurement data from a public-access databank that contains procurement information of the Brazilian Federal Government. Each procured item was cross-referenced to its active drug approval status in the Brazilian National Register (DOU). Exploratory analysis and trend measures were performed for the variables for mapping and characterizing the purchases of non-market approved drugs. Results: 614 (0.14%) purchases in ten years corresponding to 65 unlicensed medicines – some of which had orphan drug status – and 48 different active substances; with a growing trend in recent years. Medicines in 51% of purchases were procured before obtaining marketing approval – with eventual refusals occurring in 17.8% and cancellation due to lack of efficacy and/or safety concerns in 1.1%. Health litigation accounted for 81.9% of purchases and growing in recent years. Conclusions: Overall a low rate of unlicensed medicine use. However, there are concerns given the current regulations in Brazil and the recent increase in the use of unlicensed medicines with increased litigation.
KW - federal government
KW - procurement
KW - Brazil
KW - medicines
KW - licensing
UR - http://www.tandfonline.com/loi/ierp20
U2 - 10.1080/14737167.2017.1311209
DO - 10.1080/14737167.2017.1311209
M3 - Article
VL - 17
SP - 607
EP - 613
JO - Expert Review of Pharmacoeconomics and Outcomes Research
JF - Expert Review of Pharmacoeconomics and Outcomes Research
SN - 1473-7167
IS - 6
ER -